New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
08:18 EDTPCYCPharmacyclics reports sNDA for Imbruvica accepted, priority review granted
Pharmacyclics announced that the FDA has accepted for filing its suplemental new drug application to support the review of Imbruvica in the treatment of patients with CLL and SLL who have received at least one prior therapy for a full approval. The target PDUFA date by which the FDA is planning to finalize the review of this application is October 7.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
08:14 EDTPCYCPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
October 17, 2014
08:57 EDTPCYCPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTPCYCPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:34 EDTPCYCPharmacyclics management to meet with JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use